Merck & Co, INC 8-K filings

Merck & Co., Inc. announced second-quarter 2026 financial results, highlighting $16.6 billion in worldwide sales with 5% growth, driven by oncology and animal health, alongside key regulatory approvals and clinical milestones.

Merck & Co. shareholders re-elected all director nominees and ratified the appointment of the company's independent auditor at the 2026 Annual Meeting.

Merck & Co., Inc. has successfully closed an underwritten public offering of $6 billion in aggregate principal amount of senior notes across seven different series.

Merck & Co. announced first-quarter 2026 financial results, reporting $16.3 billion in worldwide sales and raising its full-year financial outlook.

Merck announced robust fourth-quarter and full-year 2025 financial results, driven by oncology and new product launches, while outlining a strategic 2026 outlook impacted by a major acquisition charge.

Merck & Co., Inc. successfully closed an underwritten public offering of $8 billion in various senior notes with maturities ranging from 2029 to 2065.

Merck & Co., Inc. announced robust third-quarter 2025 financial results, driven by key product growth and pipeline advancements, leading to a raised full-year non-GAAP EPS forecast.

Merck & Co., Inc. completed an underwritten public offering of $6 billion in aggregate principal amount of debt securities with maturities ranging from 2027 to 2055.

Merck announced a 2% decline in second-quarter worldwide sales to $15.8 billion and lower EPS, alongside a new $3.0 billion restructuring program and a $10 billion acquisition of Verona Pharma to bolster its future growth.

Merck & Co., Inc. announced the results of its May 27, 2025 Annual Meeting of Shareholders, confirming the election of all director nominees, approval of executive compensation, and ratification of its independent auditor, while rejecting all shareholder proposals.

Merck reports a slight decrease in overall sales for Q1 2025, but highlights growth in KEYTRUDA, WINREVAIR, and Animal Health, alongside pipeline advancements and revised full-year EPS guidance.

Merck announces a 7% increase in both fourth-quarter and full-year worldwide sales for 2024, driven by strong performance from KEYTRUDA, WINREVAIR, and Animal Health.

Merck & Co. has announced the appointment of Surendralal Karsanbhai to its Board of Directors and has also amended its bylaws to update indemnification provisions.

Merck's third-quarter 2024 results show a 4% increase in worldwide sales, reaching $16.7 billion, with a 7% increase excluding foreign exchange impacts.

Merck's second-quarter 2024 results show a 7% increase in worldwide sales, reaching $16.1 billion, with a notable 16% growth in Keytruda sales.

MSD Netherlands Capital B.V., a subsidiary of Merck & Co., Inc., has successfully closed a $3.4 billion underwritten public offering of senior notes.

Merck's first quarter 2024 results show a 9% increase in total worldwide sales, reaching $15.8 billion, driven by strong growth in oncology and vaccine products.

Merck & Co. reports that board member Peter C. Wendell will retire at the company's 2024 annual meeting.

Merck's fourth-quarter and full-year 2023 results show sales growth driven by oncology and vaccines, but are impacted by a significant charge related to a collaboration with Daiichi Sankyo and restructuring costs.